Home
News
292
Results found
-
New possibilities for improving cancer immunotherapy
The effectiveness of cancer immunotherapy can be enhanced by blocking certain genes in immune cells, as has now been demonstrated by new research led by Oncode Investigator Daniel Peeper (The Netherlands Cancer Institute). The researchers set out to understand why T-cells lose their fitness, as this impairs tumor control and thus affects the success of treatment. -
A New Tool for Understanding Protein Interactions at the Molecular Level
We are proud to announce the launch of a new research tool based on the Protein A -TurboID - Proximity Biotinylation enzyme developed by Oncode Investigator Michiel Vermeulen (Radboud University). This innovative technology promises to advance the field of interaction proteomics and was facilitated through a license from Oncode Institute. -
Detection of specific DNA signature colon cancer is now improved
Researchers can better detect a specific 'signature' in DNA thanks to new techniques. Certain strains of the E. coli bacteria cause a DNA signature that occurs in people with colon cancer. This group of abnormalities in the DNA is not enough by itself to cause colon cancer. But it is one of the steps in the development of the disease. -
Oncode Investigator Ton Schumacher selected to tackle one of the Cancer Grand Challenges
Today, Cancer Grand Challenges - the prestigious global research funding initiative co-founded by Cancer Research UK and the National Cancer Institute - announced the five teams that have been selected to drive team science on a global scale. -
First patients included in CPoC study towards less radical treatments for vulvar cancer
Research from the lab of Oncode Investigator Sjoerd van der Burg and Gynecologic Oncologist Mariette van Poelgeest strongly supports a role for the immune system towards a better clinical response to the standard treatment of vulvar cancer. This current standard treatment is radical and leads to long-lasting side effects. -
Dianda Veldman elected as Patient Representative to the Supervisory Board of Oncode Institute
On behalf of the Chair of the Supervisory Board, Melvin Samsom, we are pleased to announce that Dianda Veldman has been elected as a new member of the Supervisory Board of Oncode Institute, as a Patient Representative. With a rich background in patient advocacy and extensive experience in leadership roles, she brings a wealth of knowledge to her new position. -
Oncode Investigators Ruben van Boxtel, Puck Knipscheer and Jop Kind awarded prestigious NWO Vici grant
Three Oncode Investigators – Ruben van Boxtel (Princess Máxima Center), Puck Knipscheer and Jop Kind (both Hubrecht Institute) – were awarded the prestigious NWO Vici grant today. Using the grant, van Boxtel can further expand his research line into the late effects of childhood cancer, and how these are reflected at a molecular cell level. -
Een vrouw met een missie: wetenschappelijke ontdekkingen vertalen naar oplossingen voor patiënten
Een wetenschappelijke ontdekking moet een lange, complexe en noodzakelijke reis afleggen voordat het kankerpatiënten kan bereiken, of het nu gaat om een diagnostisch instrument of een therapie. Bij Oncode Institute zorgt ons Valorization Team ervoor dat de wetenschappelijke bevindingen van onze onderzoekers deze reis maken en daarin succesvol zijn. -
A woman with a mission: turning discoveries into solutions for patients
A scientific discovery needs to take a long, complex and necessary journey before it can reach cancer patients, whether as a diagnostic tool or a therapy. At Oncode Institute, our Valorization Team puts the scientific findings of our Investigators on this journey, and makes sure it is successful. But this process is often little understood. -
Moeten patiënten altijd meedenken bij onderzoek? Ja, graag!
Elk jaar organiseren de Borstkanker Onderzoeks Groep (BOOG) en Borstkankervereniging Nederland (BVN) een bijeenkomst voor de Patiënt Advies Groep (PAG). Daarin adviseert een aantal patiëntvertegenwoordigers de BOOG-onderzoekers over hun klinische onderzoek naar borstkanker. -
Should patients always participate in research? Yes, please!
Every year, the Breast Cancer Research Group (BOOG) and Breast Cancer Society Netherlands (BVN) organise a Patient Advisory Group (PAG) meeting. During this meeting, a number of patient representatives advise BOOG researchers on their clinical breast cancer research. -
New research uncovers novel starting points for therapy for hereditary breast and ovarian cancer
Carriers of a hereditary mutation in the BRCA1 gene have a highly increased risk of developing breast and ovarian cancer. This is because BRCA1 does not function in this population, which means that DNA breaks are not repaired properly. This leads to various errors in the DNA that can cause tumor growth. -
Unlocking the secrets of proteins: Oncode Institute's first masterclass of 2023 fully booked
In a resounding success, we finished 2023 with a fully booked live masterclass, delving into the intricate world of structural biology. Kindly organized by Oncode Investigators Titia Sixma and Anastassis Perrakis, this event was hosted at the NKI. -
All about science: the 2023 KIT Meeting Wrap Up
When the end of the year is approaching, it means it’s time to gather together at the iconic Royal Tropical Institute in Amsterdam for two days filled with science and networking. -
Oncode Institute zoekt een Communicatie Specialist (32-40 uur per week)
Ben jij op zoek naar een mooie baan binnen een organisatie waar je impact kan maken? Solliciteer dan nu voor de functie van Communicatie Specialist bij Oncode Institute. Oncode Institute is een kankeronderzoeksinstituut in hartje Utrecht dat als doel heeft om de resultaten van onderzoek te vertalen naar impact op patiënten en de samenleving. Wil jij daaraan bijdragen?